natgillin/translations-raw huggingface dataset:
Other medical conditions such as myeloma or chronic lymphocytic leukaemia can also reduce the level of antibodies in your blood.
Tudi nekatera zdravstvena stanja, kot na primer mielom ali kronična limfocitna levkemija, prav tako lahko zmanjšajo število protiteles v vaši krvi.
Raising antibody levels by regular injections of Flebogammadif will help your body fight off infections.
Višanje ravni protiteles z rednim infundiranjem zdravila Flebogammadif bo vašem telesu pomagalo pri boju proti okužbam.
It is used to treat Guillain Barré syndrome, where the immune system damages the nerves and hinders them from working properly.
Uporablja se za zdravljenje Guillain- Barréjevega sindroma, kjer imunski sistem poškoduje živce in ovira njihovo pravilno delovanje.
It is used to treat Kawasaki disease, an illness in children where the blood vessels (arteries) in the body become enlarged.
Uporablja se za zdravljenje Kawasakijevega sindroma, otroške bolezni pri kateri se v telesu povečajo krvne žile (arterije).
It is used in bone marrow transplantation, when you are given bone narrow cells from another person.
Uporablja se pri presaditvi kostnega mozga, ko prejmete kostni mozeg druge osebe.
The antibodies in Flebogammadif help to stop infections and help to stop your body rejecting the new cells.
Protitelesa v zdravilu Flebogammadif pomagajo pri zatiranju okužb in tudi v primerih, ko vaše telo zavrača nove celice.
It is used to treat a condition called idiopathic thrombocytopenic purpura (ITP), where the number of platelets in your blood stream is greatly reduced.
Uporablja se za zdravljenje bolezni, ki se imenuje idiopatska trombocitopenična purpura (ITP), kjer je število trombocitov v vaši krvi močno zmanjšano.
Injection of Flebogammadif results in an increase in the number of platelets, and an improvement in your condition.
Infundiranje zdravila Flebogammadif povzroči povečanje števila trombocitov in izboljšanje vašega stanja.
In children with the acquired immune deficiency syndrome (AIDS), it can be used to prevent troublesome infections.
Pri otrocih s sindromom pridobljene imunske pomanjkljivosti (AIDS) se lahko uporablja za preprečevanje težavnih okužb.
If you have any question about use of Flebogammadif please ask your doctor.
Če imate kakšno vprašanje glede zdravila Flebogammadif, se posvetujte s svojim zdravnikom.
BEFORE YOU USE FLEBOGAMMADIF
KAJ MORATE VEDETI, PREDEN BOSTE UPORABILI ZDRAVILO FLEBOGAMMADIF
Do not use Flebogammadif
Ne uporabljajte zdravila Flebogammadif
- if you are allergic (hypersensitive) to human normal immunoglobulin or any of the other
- če ste alergični na (preobčutljivi za) humani polispecifični imunoglobulin ali katerokoli
ingredients of Flebogammadif (see special warnings about excipients at the end of this section).
sestavino zdravila Flebogammadif (glejte posebna opozorila za pomožne snovi na koncu poglavja).
- if you have immunoglobulin A (IgA) deficiency with anti-IgA antibodies.
- če imate pomanjkanje imunoglobulina A (IgA) s protitelesi anti- IgA.
- fructose intolerance.
- če imate intoleranco za fruktozo.
Take special care with Flebogammadif
Bodite posebno pozorni pri uporabi zdravila Flebogammadif
Certain adverse reactions may occur more frequently: • in case of high rate of infusion. • if you have hypo- or agammaglobulinaemia (a condition implying low immunoglobulin levels in your blood) with or without IgA deficiency. • if you are having Flebogammadif for the first time, or it is a long time since your last infusion (e. g. several weeks).
Določeni neželeni učinki se lahko pojavijo pogosteje: • v primeru velike hitrosti infundiranja. • če imate hipo - ali agamaglobulinemijo (stanje, pri katerem imate v krvi nizke ravni imunoglobulina) z ali brez pomanjkanja IgA. • če prejemate zdravilo Flebogammadif prvič ali je od predhodne infuzije preteklo veliko časa (npr. več tednov).
You will be watched carefully until an hour after the infusion to detect potential adverse signs.
Da bi lahko odkrili morebitne neželene učinke, vas bodo še eno uro po infuziji skrbno opazovali.
Rarely, human normal immunoglobulin can induce a fall in blood pressure with allergic reaction, even if you had tolerated previous treatment with human normal immunoglobulin.
V redkih primerih lahko humani polispecifični imunoglobulin sproži padec krvnega tlaka z alergično reakcijo, celo če ste dobro prenašali predhodno zdravljenje s humanim polispecifičnim imunoglobulinom.
Patient with pre-existing risk factors
Bolniki s predhodno obstoječimi dejavniki tveganja
Please tell your doctor if you have any other condition and/ or illness, as caution is required.
Obvestite svojega zdravnika, če imate katerokoli stanje in/ ali bolezen, saj je potrebna previdnost.
In particular, tell your doctor if you have: • diabetes • high blood pressure • history of vascular disease or thrombosis • overweight • blood volume decrease • diseases which increase blood viscosity • advanced age
Še posebej obvestite svojega zdravnika, če imate: • sladkorno bolezen • visok krvni tlak • žilna obolenja ali trombozo • prekomerno težo • zmanjšan volumen krvi • bolezni, ki povečujejo viskoznost krvi • visoko starost
If you have a kidney problem, your doctor should consider whether to stop treatment since cases of acute renal failure have been reported in patients receiving IVIg therapy, generally in patients with risk factors.
Če imate ledvične težave, naj vaš zdravnik premisli o prekinitvi zdravljenja, saj so pri bolnikih, ki so se zdravili z intravenskim imunoglobulini (IVIg) poročali o akutni odpovedi ledvic, predvsem pri bolnikih z dejavniki tveganja.
Tell your doctor, even when any of the above-mentioned circumstances had happened to you in the past.
Obvestite svojega zdravnika, tudi če ste imeli katero od zgornjih stanj/ bolezni v preteklosti.
These include careful selection of blood and plasma donors to make sure those at risk of carrying infections are excluded, and the testing of each donation and pools of plasma for signs of virus/ infections.
Med slednjimi so skrben izbor darovalcev krvi in plazme, da je zagotovljena izključitev prenašalcev okužb in preiskovanje vsake darovane enote ter združene plazme za pokazatelje virusov/ okužb.
Despite these measures, when
Proizvajalci teh zdravil pri obdelovanju krvi ali plazme prav tako vključujejo postopke,
23 medicines prepared from human blood or plasma are administered, the possibility of passing on infection cannot be totally excluded.
Kljub tem ukrepom pri uporabi zdravil, ki so pripravljeni iz človeške krvi ali plazme, ni mogoče popolnoma izključiti možnosti prenosa okužbe.
The measures taken are considered effective for enveloped viruses such as human immunodeficiency virus (HIV), hepatitis B virus and hepatitis C virus, and for the non-enveloped hepatitis A and parvovirus B19 viruses.
Ti ukrepi so učinkoviti pri virusih z ovojnico kot so virus imunske pomanjkljivosti (HIV), virus hepatitisa B in hepatitisa C in pri virusih brez ovojnice hepatitisa A in parvovirusu B19.
Immunoglobulins have not been associated with hepatitis A or parvovirus B19 infections possibly because the antibodies against these infections, which are contained in the product, are protective.
Imunoglobulinov ne povezujejo z okužbami s hepatitisom A ali parvovirusom B19 morda zato, ker protitelesa v zdravilu varujejo pred temi okužbami.
Please tell your doctor or pharmacist if you are taking or have recently taken any other medicines, including medicines obtained without a prescription.
• Obvestite svojega zdravnika ali farmacevta, če jemljete ali ste pred kratkim jemali katerokoli zdravilo, tudi če ste ga dobili brez recepta.
• Effects on vaccines:
• Učinki na cepiva:
Flebogammadif may reduce the effectiveness of certain type of vaccines such as measles, rubella, mumps and varicella.
Flebogammadif lahko zmanjša učinkovitost določenih vrst cepiv, kot so cepiva proti ošpicam, rdečkam, mumpsu in noricam.
If you are having a blood test after receiving Flebogammadif, please tell the analyst or your doctor that you have been given this medicine.
Če imate po prejemu zdravila Flebogammadif preiskave krvi, obvestite osebo, ki kri analizira ali svojega zdravnika, da ste prejeli omenjeno zdravilo.
The level of certain antibodies can rise.
Raven določenih protiteles se lahko zviša.
Ask your doctor or pharmacist for advice before taking any medicine.
Posvetujte se s svojim zdravnikom ali s farmacevtom, preden vzamete katerokoli zdravilo.
If you are pregnant or breast-feeding you must tell your doctor.
Če ste noseči ali dojite, morate to povedati svojemu zdravniku.
Your doctor will decide if Flebogammadif can be used during pregnancy and lactation.
Vaš zdravnik se bo odločil ali se lahko uporabi zdravilo Flebogammadif med nosečnostjo in dojenjem.
Dizziness can sometimes occur and might affect the ability to drive and use machines.
Včasih se lahko pojavi omotica, ki lahko vpliva na sposobnost vožnje in upravljanja s stroji.
Important information about some of the ingredients of Flebogammadif
Pomembne informacije o nekaterih sestavinah zdravila Flebogammadif
Special warnings about ingredients:
Posebna opozorila za sestavine:
This medicine contains 50 mg of sorbitol per ml as excipient.
To zdravilo vsebuje kot pomožno snov 50 mg sorbitola na ml.
If you have been told by your doctor that you have an intolerance to some sugars, contact your doctor before taking this medicine.
Če vam je zdravnik rekel, da imate intoleranco za nekatere sladkorje, se pred uporabo zdravila obrnite na zdravnika.
Special precautions should be taken with babies and young children because this intolerance may not yet be diagnosed and may be fatal.
Posebni varnostni ukrepi so potrebni pri dojenčkih in malih otrocih, ker ta intoleranca morda še ni bila diagnosticirana in je lahko smrtna.
HOW TO USE FLEBOGAMMADIF
KAKO UPORABLJATI ZDRAVILO FLEBOGAMMADIF
Flebogammadif is given by injection into your veins (intravenous administration).
Zdravilo Flebogammadif se daje z infuzijo v vene (intravenska uporaba).
It may be self administered if you have been fully trained by hospital staff.
Infuzijo lahko opravite tudi sami, če so vas zdravstveni delavci v celoti podučili o uporabi.
You must never self administer it alone; a responsible adult must be always present.
Nikoli ne opravljajte infuzije sami, zmeraj mora pri infundiranju biti prisotna odgovorna odrasla oseba.
The dose that you will be given will depend on your weight and will be worked out by your doctor.
Količino odmerka bo izračunal vaš zdravnik.
At the beginning of your infusion you will receive Flebogammadif at a slow rate (0.01-0.02 ml/ kg/ min).
Na začetku infuzije boste prejeli zdravilo Flebogammadif počasi (0, 01– 0, 02 ml/ kg/ min).
Depending on how comfortable you feel, your doctor may then gradually increase the infusion rate (up to 0.1 ml/ kg/ min).
Odvisno od tega kako udobno se boste počutili, lahko zdravnik postopoma poveča hitrost infuzije (do 0, 1 ml/ kg/ min).
24 The solution should be clear or slightly opalescent.
Raztopina mora biti bistra ali rahlo opalescentna.
Do not use Flebogammadif if you notice that the solution is cloudy or has deposits.
Ne uporabljajte zdravila Flebogammadif, če opazite, da je raztopina motna ali ima usedlino.
If you use more Flebogammadif than you should
23 Če ste uporabili večji odmerek zdravila Flebogammadif, kot bi smeli
If you get more Flebogammadif than you should, your body may take on too much fluid.
Če ste uporabili večji odmerek zdravila Flebogammadif, kot bi smeli, ste s tem lahko v vaše telo vnesli preveč tekočine.
If you forget to use Flebogammadif
Če ste pozabili uporabiti zdravilo Flebogammadif
Tell your doctor or pharmacist immediately and follow his/ her instructions.
Takoj obvestite svojega zdravnika ali farmacevta in upoštevajte navodila.
You must not be given a double dose to make up for a forgotten dose.
Ne vzemite dvojnega odmerka, če ste pozabili vzeti prejšnji odmerek.
Like all medicines, Flebogammadif can cause side effects, although not everybody gets them.
Kot vsa zdravila ima lahko tudi zdravilo Flebogammadif neželene učinke, ki pa se ne pojavijo pri vseh bolnikih.
Tell your doctor if any of the following side effects happen during or after the infusion: • Chills • Headache • Fever • Nausea • Vomiting • Allergic reaction • Joint pain • Low blood pressure • Moderate low back pain
Če med ali po infundiranju opazite kateregakoli izmed spodaj navedenih neželenih učinkov, obvestite svojega zdravnika: • mrzlica • glavobol • povišana telesna temperatura • slabost • bruhanje • alergična reakcija • bolečina v sklepih • nizek krvni tlak • zmerna bolečina v spodnjem delu hrbtenice
Rare side effects, which are likely to occur in fewer than 1 in 1,000 patients, are: • A sudden fall in blood pressure and, in isolated cases, anaphylactic shock, even if you have shown no hypersensitivity to previous administration. • Cases of temporary meningitis (reversible aseptic meningitis). • Cases of temporary reduction in the number of the red cells in the blood (reversible haemolytic anaemia/ haemolysis). • Cases of transient cutaneous reactions. • Increase in serum creatinine level and/ or acute renal failure.
Redki neželeni učinki, ki se lahko pojavijo pri manj kot 1 od 1. 000 bolnikov, so: • Nenaden padec krvnega tlaka, v posameznih primerih pa anafilaktični šok, četudi pri predhodni uporabi niste imeli znakov preobčutljivosti. • Primeri prehodnega meningitisa (reverzibilni aseptični meningitis). • Primeri prehodnega zmanjšanja števila rdečih krvničk v krvi (reverzibilna hemolitična anemija/ hemoliza). • Primeri prehodnih kožnih reakcij. • Povečanje ravni serumskega kreatinina in/ ali akutna odpoved ledvic.
Very rare side effects, which are likely to occur in fewer than 1 in 10,000 patients or which cannot be estimated from the available data, are: • Thromboembolic reactions such as myocardial infarction, stroke, pulmonary embolism, deep vein thromboses.
Zelo redki neželeni učinki, ki se lahko pojavijo pri manj kot 1 od 10. 000 bolnikov ali se jih ne da oceniti iz razpoložljivih podatkov, so: • Tromboembolični dogodki kot so miokardni infarkt, možganska kap, pljučna embolija in globoka venska tromboza.
HOW TO STORE FLEBOGAMMMADIF
SHRANJEVANJE ZDRAVILA FLEBOGAMMMADIF
Do not use Flebogammadif after the expiry date which is stated on the label and carton after EXP.
Zdravila Flebogammadif ne smete uporabljati po datumu izteka roka uporabnosti, ki je naveden na ovojnini poleg oznake EXP.
25 Any unused product or waste material should be disposed of in accordance with local requirements.
24 Neuporabljeno zdravilo ali odpadni material zavrzite v skladu z lokalnimi predpisi.
What Flebogammadif contains
Kaj vsebuje zdravilo Flebogammadif
- The active substance is human normal immunoglobulin (IVIg).
- Zdravilna učinkovina je humani polispecifični imunoglobulin (IVIg).
One ml contains 50 mg of
En ml vsebuje 50 mg
human normal immunoglobulin, of which at least 97% is IgG.
humanega polispecifičnega imunoglobulina, ki vsebuje vsaj 97% IgG.
- The other ingredients are sorbitol and water for injections (see section 2. ‘ Before you use
- Druge sestavine so sorbitol in voda za injekcije (za nadaljnje informacije o sestavinah glejte
Flebogammadif’ for further information about ingredients).
poglavje 2. ‘ Kaj morate vedeti, preden boste uporabili zdravilo Flebogammadif ’).
What Flebogammadif looks like and contents of the pack
Izgled zdravila Flebogammadif in vsebina pakiranja
Flebogammadif is a solution for infusion.
Flebogammadif je raztopina za infundiranje.
Flebogammadif is supplied as 0.5 g/ 10 ml, 2.5 g/ 50 ml, 5 g/ 100 ml, 10 g/ 200 ml and 20 g/ 400 ml vials.
Zdravilo Flebogammadif je na voljo v vialah po 0, 5 g/ 10 ml, 2, 5 g/ 50 ml, 5 g/ 100 ml, 10 g/ 200 ml in 20 g/ 400 ml.
Pack size of 1 vial.
1 viala.
Not all sizes may be marketed.
Na trgu ni vseh navedenih pakiranj.
For any information about this medicine, please contact the local representative of the Marketing Authorisation Holder:
Za več informacij o tem zdravilu se obrnite na lokalnega zastopnika imetnika dovoljenja za promet z zdravilom.
26 Danmark Instituto Grifols, S. A.
25 Danmark Instituto Grifols, S. A.
27 Κύπρος Instituto Grifols, S. A.
26 Κύπρος Instituto Grifols, S. A.
Detailed information on this medicine is available on the European Medicines Agency (EMEA) website: http: / /www. emea. europa. eu
Podrobne informacije o zdravilu so objavljene na spletni strani Evropske agencije za zdravila (EMEA): http: // www. emea. europa. eu
In replacement therapy the dosage will be adapted dependent on your pharmacokinetic and clinical response.
Pri nadomestnem zdravljenju bo odmerek prilagojen na podlagi farmakokinetičnega in kliničnega odziva.
The following dosage regimens are given as a guideline:
Naslednji režimi odmerjanja so dani kot smernice:
The dosage recommendations are summarised in the following table:
Priporočljivi odmerki so povzeti v naslednji razpredelnici:
Children with AIDS
Otroci, oboleli za AIDS- om Imunomodulacija:
1.6 - 2 g/ kg or
1, 6– 2 g/ kg
in several doses for 2 - 5 days in association with acetylsalicylic acid
obdobju 2– 5 dni, ob sočasnem zdravljenju z acetilsalicilno kislino
Flebogammadif should be infused intravenously at an initial rate of 0.01-0.02 ml/ Kg/ min for the first thirty minutes.
Flebogammadif infundirajte intravensko z začetno hitrostjo 0, 01– 0, 02 ml/ kg/ min prvih trideset minut.
A significant increase in median platelet levels was achieved in a clinical trial in chronic ITP patients (64,000/ µl) although it did not reach normal levels.
Znatno zvišanje srednje ravni trombocitov so dosegli pri klinični raziskavi pri bolnikih s kronično ITP (64, 000/ µl), čeprav niso dosegli normalnih ravni.
Flebogammadif should not be mixed with other medicines or intravenous solutions and it should be administered by a separate intravenous line.
Zdravila Flebogammadif ne smete mešati z drugimi zdravili ali intravenskimi raztopinami, uporabiti se mora z ločeno infuzijo.
It is strongly recommended that every time Flebogammadif is administered, the name and batch number of the product is recorded in order to maintain a record of the batches used.
Zelo priporočljivo je, da vsakič, ko uporabljate zdravilo Flebogammadif, zabeležite ime in serijsko številko zdravila, da tako vodite evidenco o uporabljenih serijah zdravila.
What is Fluticasone Furoate GSK?
Kaj je zdravilo Fluticasone Furoate GSK?
Fluticasone Furoate GSK is a nasal spray that contains the active substance fluticasone furoate.
Zdravilo Fluticasone Furoate GSK je pršilo za nos, ki vsebuje zdravilno učinkovino flutikazonfuroat.
This medicine is the same as Avamys, which is already authorised in the European Union (EU).
To zdravilo je enako zdravilu Avamys, ki je že odobreno v Evropski uniji (EU).
The company that makes Avamys has agreed that its scientific data can be used for Fluticasone Furoate GSK.
Družba, ki izdeluje zdravilo Avamys, se strinja, da se lahko znanstveni podatki o tem zdravilu uporabijo tudi za zdravilo Fluticasone Furoate GSK.
What is Fluticasone Furoate GSK used for?
Za kaj se zdravilo Fluticasone Furoate GSK uporablja?
Fluticasone Furoate GSK is used to treat the symptoms of allergic rhinitis.
Zdravilo Fluticasone Furoate GSK se uporablja za zdravljenje simptomov alergijskega rinitisa.
It is often accompanied by symptoms affecting the eyes, such as irritation, watering or redness.
Pogosto ga spremljajo očesni simptomi, kot je draženje, solzenje ali pordelost oči.
Fluticasone Furoate GSK is for use in adults and children aged six years and over.
Zdravilo Fluticasone Furoate GSK se uporablja pri odraslih in otrocih, starih šest let in več.
How is Fluticasone Furoate GSK used?
Kako se zdravilo Fluticasone Furoate GSK uporablja?
The recommended dose of Fluticasone Furoate GSK for adults and adolescents aged 12 years and over is two sprays in each nostril once a day.
Priporočeni odmerek zdravila Fluticasone Furoate GSK pri odraslih in mladostnikih, starih 12 let in več, sta dva vpiha v vsako nosnico enkrat dnevno.
This can be reduced to one spray in each nostril once symptoms are controlled.
Ko je dosežen zadosten nadzor nad simptomi, je odmerek mogoče zmanjšati na en vpih v vsako nosnico.
For children between six and 12 years of age, the recommended dose is one spray in each nostril once a day, although this can be increased to two sprays if symptoms are not controlled.
Pri otrocih, starih med šest in 12 let, je priporočeni odmerek en vpih v vsako nosnico enkrat dnevno, če pa s tem odmerkom ne dosežemo zadostnega nadzora nad simptomi, ga lahko povečamo na dva vpiha.
To get the most benefit from the medicine, it should be used regularly and at the same time every day.
Največji učinek zdravila dosežemo, če ga uporabljamo redno in vsak dan ob istem času.
It usually starts to work from eight hours after the first spray, but it may take several days to get the maximum benefit.
Zdravilo običajno začne učinkovati osem ur po prvi uporabi, vendar pa se največji učinek lahko pokaže šele nekaj dni po začetku zdravljenja.
Fluticasone Furoate GSK should only be used for as long as the patient is exposed to the allergen, such as pollen, house dust mites or other animals.
Zdravilo Fluticasone Furoate GSK se lahko uporablja samo toliko časa, dokler je bolnik izpostavljen alergenom, kot so cvetni prah, hišne pršice ali druge živali.
How does Fluticasone Furoate GSK work?
Kako zdravilo Fluticasone Furoate GSK deluje?
The active substance in Fluticasone Furoate GSK, fluticasone furoate, is a corticosteroid.
Zdravilna učinkovina v zdravilu Fluticasone Furoate GSK, flutikazonfuroat, je kortikosteroid.
It works in a similar way to naturally-occurring corticosteroid hormones, dampening down the activity of the immune system by attaching to receptors in various types of immune cell.
Deluje podobno kot naravno prisotni kortikosteroidni hormoni, in sicer tako, da z vezavo na receptorje v različnih imunskih celicah zavira aktivnost imunskega sistema.
This leads to a reduction of the release of substances that are involved in the inflammation process, such as histamine, reducing the symptoms of allergy.
Posledica tega je zmanjšano sproščanje snovi, ki sodelujejo pri vnetnem procesu, kot so histamini, s tem pa se zmanjšajo simptomi alergije.
How has Fluticasone Furoate GSK been studied?
Kako je bilo zdravilo Fluticasone Furoate GSK raziskano?
The effects of Fluticasone Furoate GSK were first tested in experimental models before being studied in humans.
Učinki zdravila Fluticasone Foroate GSK so bili najprej preizkušeni na poskusnih modelih, nato pa so jih raziskali pri ljudeh.
The effectiveness of Fluticasone Furoate GSK was studied in six main studies involving almost 2,500 patients, which compared Fluticasone Furoate GSK with placebo (a dummy treatment).
Učinkovitost zdravila Fluticasone Furoate GSK so preučevali v šestih večjih študijah s skoraj 2 500 bolniki, v katerih so zdravilo Fluticasone Furoate GSK primerjali s placebom (zdravilom brez zdravilne učinkovine).
The first four studies looked at Fluticasone Furoate GSK used in adults and adolescents aged 12 years or over.
V prvih štirih študijah so preučevali uporabo zdravila Fluticasone Furoate GSK pri odraslih in mladostnikih, starih 12 let in več.
Three were short-term studies lasting two weeks and involved a total of 886 patients with seasonal allergic rhinitis (hay fever), while the fourth lasted four weeks and involved 302 patients with perennial (non- seasonal) allergies, such as allergies to animal dander (skin and hair).
Tri med njimi so bile kratkoročne študije, ki so trajale dva tedna in so vključevale skupno 886 bolnikov s sezonskim alergijskim rinitisom (senenim nahodom), četrta pa je trajala štiri tedne in je vključevala 302 bolnika s celoletnimi (nesezonskimi alergijami), kot so alergije na živalski prhljaj (kožo in dlako).
The last two studies were carried out in children aged between two and 11 years, in which two doses of Fluticasone Furoate GSK were compared with placebo.
Zadnji dve študiji sta bili izvedeni pri otrocih, starih od dve do 11 let, pri katerih so zdravilo Fluticasone Furoate GSK primerjali s placebom.
What benefit has Fluticasone Furoate GSK shown during the studies?
Kakšne koristi je zdravilo Fluticasone Furoate GSK izkazalo med študijami?